Clinical Trial

Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To assess the efficacy of FVIII/VWF Complex (Human), Alphanate® as replacement therapy in preventing excessive bleeding in subjects with congenital Type 3 von Willebrand Disease (VWD) who undergo surgical procedures.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2007-11-07; most recent amendment 2023-08-24.
Status change: Recruiting → Active, Not Recruiting 2018-03-08
Trial Details
NCT Number NCT00555555
Lead Sponsor Grifols Biologicals, LLC
Conditions Von Willebrand Disease
Enrollment 15 participants
Start Date 2007-09
Primary Completion 2028-12 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2023-08-25